Furthermore, TNFR2 gene expression analysis and IHC validation highlighted the involvement of TNFR2 in MGN pathogenesis, supporting its potential as a therapeutic target for mitigating renal inflammation and preserving renal function. The gene discussed is TNFRSF1B; the disease is idiopathic membranous glomerulonephritis.